Eylea® (aflibercept) injection sbla for treatment of retinopathy of prematurity (rop) accepted for fda priority review

Rop is a leading cause of childhood blindness worldwide tarrytown, n.y. , oct. 12, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced the u.s. food and drug administration (fda) has accepted for priority review the supplemental biologics license application (sbla) for eylea® (aflibercept) injection to treat retinopathy of prematurity (rop) in preterm infants.
REGN Ratings Summary
REGN Quant Ranking